

Date: Februray 06, 2024

To,  
Corporate Relationship Department,  
**BSE Limited**  
PJ Towers, Dalal Street,  
Mumbai 400001, MH

**Stock Code: 542248**

**Subject: Press Release**

Dear Sir/Madam,

This is further to our letter of the date intimating the Un-Audited Standalone and Consolidated Financial Results Financial Results of the Company for the quarter ended December 31, 2023, enclosed is a copy of the Press Release on the same for your records.

The above information is being hosted on the Company's website [www.deccanhealthcare.co.in](http://www.deccanhealthcare.co.in) in terms of Regulation 46 of the Listing Regulations, as amended.

You are requested to take the same on record.

Thanking You,  
For and on behalf of  
**Deccan Health Care Limited**



\_\_\_\_\_  
Vaishali Gaganam  
Company Secretary  
**Encl: a/a**

**Registered office:**

CIN: L72200TG1996PLC024351. Estd: 1996  
Address : H.No. 6-3-348/4, Dwarkapuri  
Colony, Punjagutta, Hyderabad,  
Telangana-500082

**Innovation Hub & manufacturing:**

Address: Plot No.13, Sector-03, (SIDCUL), IIE,  
Panthnagar, Udam Singh Nagar  
-263153,U.K., India

**Deccan Health Care Ltd Reports Impressive 50% YoY Revenue Growth for 9M FY24, Accompanied by a Remarkable 16x Increase in YoY Profit After Tax (PAT)**

- ▶ Total revenue from operations recorded at ₹1,534 lakh during Q3FY24, Up by 77.5% (YoY).
- ▶ EBITDA for Q3FY24 stands at ₹124 lakh, representing a positive growth with an EBITDA margin of 8.1%.
- ▶ PAT for Q3FY24 turned positive stands at ₹55 lakh with a PAT Margin of 3.6%.

**Hyderabad, 6<sup>th</sup> February 2024:** Deccan Healthcare Limited (BSE: 542248), a leading nutraceuticals product company, with an aim to help consumers age gracefully, reduce risk of disease, prevent disease, and live a better quality of life, today announced its unaudited financial results for the Q3 & 9M FY24 quarter which ended 31st December 2023.

**Financial Performance for Q3 & 9M FY24 (₹ in Lakh):**

Parameters	Q3FY24	Q3FY23	YoY	9M FY24	9M FY23	YoY	FY23
Revenue	1,534	865	77.5%	4,376	2,916	50.1%	4,502
EBITDA	124	(19)	NA	309	126	145.0%	206
EBITDA Margin	8.1%		NA	7.1%	4.3%	+274 bps	4.6%
PAT	55	(43)	NA	139	9	16x	40
PAT Margin	3.6%		NA	3.2%	0.3%	+289 bps	0.9%

Commenting on the results, Dr. Minto Purshotam Gupta, Chairman & Managing Director of Deccan Healthcare Limited said, "I am pleased to announce that our efforts have yielded promising results in Q3FY24. Our total revenue from operations experienced a significant 77.5% increase year-on-year, reaching ₹1,534 lakh. Moreover, our PAT turned positive at ₹55 lakh, with a PAT Margin of 3.6%. Additionally, our EBITDA for Q3FY24 stands at ₹124 lakh, indicating positive growth and an EBITDA margin of 8.1%.

Moving forward, we remain dedicated to achieving sustainable growth and maximizing shareholder value. This commitment is reflected in our intensified investments in our brand portfolio and our unwavering focus on innovation. We continue to maintain a flexible and responsible organizational structure, aimed at delivering outstanding products and driving positive disruption for sustainable growth. Our recent efforts include redirecting resources towards strategic marketing initiatives to revitalize business expansion and adapting to evolving consumer behaviors. Additionally, we are proud to introduce new offerings such as Ashwagandha-based millet cookies, Omega 3-based millet cookies, multi-seed millet cookies, and iron-infused bars, showcasing our dedication to product diversification and meeting diverse customer needs. We sincerely thank you for your continued support, which remains pivotal to our success."

**About Deccan Healthcare Limited (BSE: 542248):**

Deccan Healthcare Limited, established in 1996, is a leading nutraceuticals company committed to helping consumers age gracefully and enhance their overall well-being. With a focus on innovation, supply chains, and brand equity, the company consistently delivers superior value to its customers. Popular for its Fast-Moving Consumer Healthcare products, including food pills and meals, Deccan Healthcare addresses 52+ wellness goals, preventing over 200+ diseases. The success of the BE YOUNG brand, particularly through e-commerce, reflects the company's dedication. Moreover, the international expansion with the STAY YOUNG brand further demonstrates their dynamic approach. Deccan Healthcare Limited stands out as a positive force in the nutraceuticals industry, prioritizing consumer health and sustained growth.

**Safe Harbor:**

*Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential, and target dates for project-related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.*

**For further details please contact:**

DECCAN HEALTHCARE LIMITED CIN: L72200TG1996PLC024351	
<p><b>Dr. Minto Purshotam Gupta,</b> Chairman &amp; Managing Director</p> <p>W: <a href="http://www.deccanhealthcare.co.in">www.deccanhealthcare.co.in</a></p>	<p><b>Mr. Ritesh Singh,</b> Investor Relations Consultant</p> <p>M: +91 83293 85762 E: <a href="mailto:ritesh.singh@rikcapital.in">ritesh.singh@rikcapital.in</a> W: <a href="http://www.rikcapital.in">www.rikcapital.in</a></p>